Funded Biotechnology Startups in Chicago
Disclosed funding in this Chicago biotechnology set is highly skewed: Paragon Biosciences raised $185M on 2022-11-04, which dwarfs the next-largest disclos…
Disclosed funding in this Chicago biotechnology set is highly skewed: Paragon Biosciences raised $185M on 2022-11-04, which dwarfs the next-largest disclosed rounds in the $85M–$30M band (Vanqua Bio $85M on 2021-09-14; several $30M rounds including MAIA Biotechnology on 2026-03-02 and Grove Biopharma on 2025-04-23). At the other end, the smallest disclosed amount is $80K (Dimension Inx on 2025-02-18), while several rounds cluster tightly around $2M–$4M (e.g., Clever Carnivore $2M on 2025-11-08; Madison Scientific $3M on 2025-09-10; OrisDX $4M on 2025-06-10).
Timing also shows concentration near the present: the most recent entry is SyntaxBio on 2026-06-21, and the 24 rows span 2021-09-14 through 2026-06-21. Stages and disclosure are mixed: 5 entries are labeled “Series Unknown” and 1 is “undisclosed,” leaving the remaining rounds distributed across named stages such as Seed, Series A, and Series B.
Most recent rounds
24 shownRelated listings
Frequently asked
What stands out as the largest disclosed round, and how does it compare to other disclosed amounts in this Chicago biotech list?
Paragon Biosciences’s $185M round on 2022-11-04 is the clear disclosed outlier. The next-largest disclosed amounts are $210K? (no), so the next step up is Vanqua Bio’s $85M on 2021-09-14, followed by multiple $30M rounds such as MAIA Biotechnology ($30M on 2026-03-02) and Grove Biopharma ($30M on 2025-04-23).
How extreme is the spread between the smallest and largest disclosed rounds, based on disclosed amounts only?
The smallest disclosed round shown is Dimension Inx at $80K on 2025-02-18, while the largest disclosed amount is Paragon Biosciences at $185M on 2022-11-04. That gap is far larger than the typical disclosed cluster seen around $2M–$7M entries like Clever Carnivore ($2M on 2025-11-08), Madison Scientific ($3M on 2025-09-10), and CiRC Biosciences ($7M on 2024-05-01).
Are there temporal clusters among the most recent rounds?
Yes. Multiple rounds occur in the 2025 calendar year (for example, Grove Biopharma $30M on 2025-04-23, Stately Bio $12M on 2025-05-01, and OrisDX $4M on 2025-06-10), and the list also extends heavily into 2026 with SyntaxBio $14M on 2026-06-21 and MAIA Biotechnology $30M on 2026-03-02.
What disclosure pattern appears most often in this list: named stages, “Series Unknown,” or “undisclosed”?
Named stages are present, but “Series Unknown” shows up 5 times (e.g., NovaScan $670K on 2026-05-22; MAIA Biotechnology $30M on 2026-03-02; CancerIQ undisclosed on 2024-08-21) and “undisclosed” appears once (Xeris Pharmaceuticals on 2026-06-11). The remaining entries include explicit stages like Seed (e.g., Amphix Bio $13M on 2025-12-18) and Series A (e.g., SyntaxBio $14M on 2026-06-21; Synapticure $25M on 2024-11-19).
Which stage labels recur, and do they align with specific funding-size bands?
Seed rounds in the list span a relatively wide disclosed range, from $2M entries such as Clever Carnivore (2025-11-08) and Regenerative Medical Solutions (2025-10-01) to $13M for Amphix Bio (2025-12-18). Series A entries also sit in the tens of millions when disclosed (SyntaxBio $14M on 2026-06-21; Synapticure $25M on 2024-11-19; and Grove Biopharma $30M on 2025-04-23), while Series B is represented by Vanqua Bio at $85M on 2021-09-14.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.